SG Americas Securities LLC Sells 3,256 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

SG Americas Securities LLC cut its stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) by 4.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 66,364 shares of the company’s stock after selling 3,256 shares during the quarter. SG Americas Securities LLC owned 0.09% of ORIC Pharmaceuticals worth $536,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. Creative Planning bought a new stake in ORIC Pharmaceuticals during the third quarter worth $116,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in ORIC Pharmaceuticals during the 3rd quarter worth $132,000. China Universal Asset Management Co. Ltd. grew its stake in shares of ORIC Pharmaceuticals by 71.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,568 shares of the company’s stock worth $139,000 after acquiring an additional 5,646 shares in the last quarter. Intech Investment Management LLC purchased a new stake in shares of ORIC Pharmaceuticals in the third quarter valued at about $200,000. Finally, Squarepoint Ops LLC raised its holdings in shares of ORIC Pharmaceuticals by 95.6% in the second quarter. Squarepoint Ops LLC now owns 33,984 shares of the company’s stock valued at $240,000 after purchasing an additional 16,613 shares during the last quarter. Institutional investors own 95.05% of the company’s stock.

ORIC Pharmaceuticals Trading Down 3.2 %

ORIC Pharmaceuticals stock opened at $10.42 on Friday. The business’s 50 day simple moving average is $9.24 and its 200 day simple moving average is $9.60. ORIC Pharmaceuticals, Inc. has a 12 month low of $6.33 and a 12 month high of $16.65. The company has a market cap of $735.34 million, a price-to-earnings ratio of -5.79 and a beta of 1.18.

ORIC Pharmaceuticals (NASDAQ:ORIC) last issued its earnings results on Tuesday, November 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.01). As a group, equities research analysts forecast that ORIC Pharmaceuticals, Inc. will post -1.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ORIC has been the subject of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ORIC Pharmaceuticals in a research report on Tuesday, January 14th. Wedbush reaffirmed an “outperform” rating and issued a $20.00 target price on shares of ORIC Pharmaceuticals in a report on Monday, January 13th. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of ORIC Pharmaceuticals in a research report on Monday, January 13th. Finally, Wells Fargo & Company assumed coverage on ORIC Pharmaceuticals in a research report on Thursday, October 31st. They issued an “overweight” rating and a $20.00 price objective on the stock. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, ORIC Pharmaceuticals has an average rating of “Buy” and a consensus target price of $18.29.

Insider Activity at ORIC Pharmaceuticals

In related news, insider Pratik S. Multani sold 8,850 shares of ORIC Pharmaceuticals stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $8.28, for a total value of $73,278.00. Following the completion of the transaction, the insider now directly owns 46,765 shares in the company, valued at approximately $387,214.20. The trade was a 15.91 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jacob Chacko sold 24,660 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $8.28, for a total value of $204,184.80. Following the sale, the chief executive officer now owns 778,648 shares in the company, valued at approximately $6,447,205.44. This represents a 3.07 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 42,361 shares of company stock worth $350,749. Company insiders own 5.55% of the company’s stock.

ORIC Pharmaceuticals Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.